Please login to the form below

Not currently logged in
Email:
Password:

UCB appoints new board members

Brussels-based biopharmaceutical company, UCB, has announced Bert De Graeve and Alexandre Van Damme as candidates for the Board

Brussels-based biopharmaceutical company, UCB, has announced Bert De Graeve and Alexandre Van Damme as candidates to join the Board at the company's general assembly on April 29.  After three terms on the Board, Prince Lorenz will step down at the forthcoming assembly. UCB's Board of Directors and Executive Committee thanked him for his contributions.

Bert De Graeve is chief executive officer of the Bekaert Group. He is also a member of the International Business Leaders' Advisory Council for the Mayor of Shanghai (IBLAC), president of the Flanders-China Chamber of Commerce, member of the advisory board of the Conference Board China Centre for Economics and Business in Beijing, member of the Board of the Concours Reine Elisabeth and senior member of the Conference Board New York.

Alexandre Van Damme is on the boards of Anheuser-Busch InBev and InBev-Baillet Latour (not-for-profit organisation). He is also a member of the INSEAD International Council and the Solvay Business School Consultative Council. Their appointments will broaden the skills of the Board. Following approval at the general assembly, the new Board will have eight independent members; Armand De Decker, Bert De Graeve, Peter Fellner, Jean-Pierre Kinet, Thomas Leysen, Tom McKillop, Gerhard Mayr, and Norman Ornstein.

The remaining members include Karel Boone, chairman, Evelyn du Monceau, vice chair, Roch Doliveux, executive director, Arnoud de Pret, Bridget van Rijckevorsel, Alexandre Van Damme and Gaëtan van de Werve. 

29th March 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...

Infographics